Table 4.

Characteristics of the Included Articles Reporting on Continuity Defects in Human Studies

No	Year	Authors	Number of patients	Carrier	Osteogenic tissues/BMPs [total dosage]
1.	2001	Moghadam et al.111	1	Allogenic demineralized bone matrix gel	Native human BMPs [200 mg]
2.	2002	Ferretti and Ripamonti112	6	Allogenic bone matrix	Xenogeneic BMPs [2–8 mg]
3.	2004	Warnke et al.113	1	Xenogeneic bone mineral blocks	Autologous bone marrow/rhBMP-7 [7 mg]
4.	2006	Warnke et al.114	Supplement report of Warnke et al.113
5.	2007	Herford et al.115	2	Collagen sponge	Autogenous bone/rhBMP-2 [8 mg] or rhBMP-2 [8 mg]
6.	2008	Clokie and Sandor116	10	Allogenic demineralized bone matrix in a reverse-phase medium	rhBMP-7 [not mentioned]
7.	2008	Carter et al.117	4	Collagen sponge or Collagen sponge/allogenic bone	Autogenous bone marrow/rhBMP-2 [12 mg] or rhBMP-2 [8.4 mg]
8.	2008	Herford and Boyne118	14	Collagen sponge	rhBMP-2 [4.2–6 mg]
9.	2010	Kokemueller et al.119	1	β-TCP	Autogenous bone/autogenous marrow
10.	2010	Herford and Cicciù120	1	Collagen sponge	Autogenous bone/rhBMP-2 [4.2 mg]
11.	2012	Cicciù et al.121	1	Collagen sponge/allogenic bone	rhBMP-2 [not mentioned]